STAAR Surgical Company (STAA)
Nasdaq · Healthcare · Medical Instruments & Supplies
$22.57+0.45%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.1B
- P/E (trailing)
- 282.1
- Forward P/E
- 20.3
- 52-week range
- $15.59 – $35.87
- 52-week change
- −15.91%
- EPS (trailing)
- $0.08
- Analyst rating
- 2.5 Buy
- Next earnings
- Nov 11, 2026
Fiscal year to Jan 2026
- Revenue
- $239M (−23.72%)
- Net income
- −$80.4M
- Operating margin
- −38.3%
- Diluted EPS
- −$1.62
- Free cash flow
- −$40.0M
From the company’s annual report on SEC EDGAR.
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Headquarters: Lake Forest, United States · 921 employees · staar.com